StemCells, Inc. (NASDAQ: STEM) is using its proprietary human neural stem cells for treating disorders of the central nervous system. The company has completed four phase I/II clinical trials, including one in age related macular degeneration and one in spinal cord injury – both of which achieved positive results. StemCells currently is pursuing a follow-on phase II study in chronic cervical spinal cord injury. Interim results on the first six patients in Cohort I of the studies showed gains in muscle strength in five of the six patients; four of those five subjects also demonstrated improved performance on functional tasks assessing dexterity and fine motor skills; and, four of the six patients had improvement in the anatomic level of injury. Final results from this Cohort will be available Q2 2016 with final study results available 2017. For more information, visit the company’s website at www.stemcellsinc.com